• Markets
    • icon
  • Companies
CUV · ASX

Clinuvel Pharmaceuticals Limited (ASX:CUV)

AU$16.74

 -0.84 (-4.778%)
ASX:Live
05/12/2023 04:10:44 PM
HALO Small HALO Ords HALO MQV SMALL HALO MQV HALO Momentum +8
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CUV Overview

CUV Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About CUV

Website

Clinuvel Pharmaceuticals Limited

Telephone

61.3.9660.4900

Address

Level 11 535 Bourke Street Melbourne, Victoria (VIC) 3000

Description

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

CUV Price Chart

Key Stats

Market Cap

AU$890.76M

PE

34.60

EV/EBITDA

21.7

Dividends Overview

DIV Yield

.3%

Franking

100%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 13.97 - 28.72

Trade Value (12mth)

AU$383,536.00

1 week

-7.26%

1 month

8.28%

YTD

-22.14%

1 year

-17.13%

All time high

45.88

Key Fundamentals

EPS 3 yr Growth

102.700%

EBITDA Margin

53.20%

Operating Cashflow

$37m

Free Cash Flow Return

25.30%

ROIC

21.00%

Interest Coverage

N/A

Quick Ratio

7.10

Other Data

Shares on Issue (Fully Dilluted)

52m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

4.23

CUV Announcements

Latest Announcements

Date Announcements

31 October 23

Chair's Address

×

Chair's Address

31 October 23

CEO Presentation AGM

×

CEO Presentation AGM

31 October 23

Results of Meeting

×

Results of Meeting

31 October 23

CLINUVEL Appoints New Chair

×

CLINUVEL Appoints New Chair

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report Re-issued

×

Quarterly Activities/Appendix 4C Cash Flow Report Re-issued

31 March 22

CLINUVEL Newsletter II - March 2022

×

CLINUVEL Newsletter II - March 2022

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 August 22

CLINUVEL Investor Webinar Financial Results 2022

×

CLINUVEL Investor Webinar Financial Results 2022

30 March 23

Investor Presentation - NYC Nasdaq Event

×

Investor Presentation - NYC Nasdaq Event

30 March 22

First XP-V Patient Treated in Third CUV DNA Repair Study

×

First XP-V Patient Treated in Third CUV DNA Repair Study

30 March 10

Clinuvel Corporate Presentation

×

Clinuvel Corporate Presentation

30 June 23

Two Grounds of Appeal Upheld by NICE Panel

×

Two Grounds of Appeal Upheld by NICE Panel

30 June 23

Notification regarding unquoted securities - CUV

×

Notification regarding unquoted securities - CUV

30 August 23

CLINUVEL Investor Webinar Transcript

×

CLINUVEL Investor Webinar Transcript

30 August 22

Appendix 4E and Annual Report 2022

×

Appendix 4E and Annual Report 2022

30 August 22

Dividend/Distribution - CUV

×

Dividend/Distribution - CUV

30 August 22

Revenue Growth Drives CLINUVEL's Full Year Profit

×

Revenue Growth Drives CLINUVEL's Full Year Profit

30 August 22

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

29 September 23

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 September 23

Board Changes after AGM

×

Board Changes after AGM

29 September 06

2006 Annual Report

×

2006 Annual Report

29 June 23

Presentation - Melbourne Twilight Briefing

×

Presentation - Melbourne Twilight Briefing

29 June 23

Notification of cessation of securities - CUV

×

Notification of cessation of securities - CUV

29 August 23

Appendix 4E and Annual Report to Shareholders 2023

×

Appendix 4E and Annual Report to Shareholders 2023

29 August 23

Dividend/Distribution - CUV

×

Dividend/Distribution - CUV

29 August 23

CLINUVEL delivering increases in annual revenue, profit

×

CLINUVEL delivering increases in annual revenue, profit

CUV Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock 0.50 0.42 0.62 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock 0.48 0.40 0.59 Lock Lock Lock
     Growth % Lock Lock Lock Lock 63.8 -15.6 46.6 Lock Lock Lock
     PE X Lock Lock Lock Lock 75.1 42.7 34.6 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 62.7 24.7 21.7 Lock Lock Lock
CFPS $ Lock Lock Lock Lock 0.62 0.69 0.81 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.34 0.74 0.65 Lock Lock Lock
     Growth % Lock Lock Lock Lock 148.0 10.8 18.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock 1.1 5.0 3.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.02 0.04 0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 60.0 25.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.1 0.1 0.3 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 5 9 8 Lock Lock Lock
BPS $ Lock Lock Lock Lock 2.00 2.54 3.33 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 1.99 2.54 3.33 Lock Lock Lock
     Growth % Lock Lock Lock Lock 37.1 27.2 31.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 51 52 52 Lock Lock Lock
Basic m Lock Lock Lock Lock 49 49 49 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 48 66 78 Lock Lock Lock
     Growth % Lock Lock Lock Lock 47.3 37.0 19.2 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 9 14 10 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 35 47 51 Lock Lock Lock
     Growth % Lock Lock Lock Lock 91.0 32.4 8.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock 73.4 70.9 64.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 27 29 35 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock 28 34 42 Lock Lock Lock
     Growth % Lock Lock Lock Lock 158.9 22.8 23.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock 57.4 51.5 53.2 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock 27 33 41 Lock Lock Lock
     Growth % Lock Lock Lock Lock 161.8 23.9 23.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock 55.6 50.3 52.2 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock 26 34 46 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 1 13 15 Lock Lock Lock
Net Income $m Lock Lock Lock Lock 25 21 31 Lock Lock Lock
     Growth % Lock Lock Lock Lock 64.3 -15.6 46.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock 51.5 31.8 39.1 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 19 40 37 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 0 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 18 39 36 Lock Lock Lock
     Growth % Lock Lock Lock Lock 38.4 114.2 -9.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.4 0.6 0.5 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 1 N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 83 122 157 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 109 145 195 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -81 -120 -156 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 10 19 30 Lock Lock Lock
Equity $m Lock Lock Lock Lock 99 126 165 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 100 127 165 Lock Lock Lock
     Growth % Lock Lock Lock Lock 36.4 26.8 30.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock 22.8 14.4 15.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 25.0 16.6 18.6 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock 30.5 29.2 28.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock 28.3 18.5 21.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 22.1 35.2 25.3 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -3.0 -3.6 -3.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -82.4 -95.8 -94.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 11.8 10.2 7.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 11.4 10.1 7.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 80.4 86.4 82.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 221.2 290.4 144.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 4.2 4.1 4.1 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 5.7 7.6 4.9 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.5 0.5 0.5 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 4.8 0.4 3.6 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.4 0.5 0.4 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.4 0.5 0.4 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 53.6 52.2 58.2 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 23.7 23.7 23.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 3.8 39.2 32.9 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock 22.8 14.4 15.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 25.0 16.6 18.6 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 95.0 90.5 91.9 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock 23.8 15.1 17.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 63.9 47.9 74.7 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 86.4 89.7 89.5 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 150.3 137.6 164.2 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 46.7 26.6 15.7 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 103.6 111.1 148.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.3%

Franking Level

100%

DPSg

25.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Expected Dividend Cashflow

Dividend Clarity,
Enhanced
Strategy

Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

4.25%

Value ($M)

38

Prior Change

N/A

7 Day Change

-0.80%

1 Month Change

N/A

3 Month Change

1.20%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CUV Shortsell

Frequently Asked Questions

The current share price of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$16.74.
The 52-week high share price for Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$28.72.
The 52-week low share price for Clinuvel Pharmaceuticals Limited (CUV:ASX)? is AU$13.97.
The current TTM dividend payout for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 0.30.
The last dividend payment of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AU$0.05.
Clinuvel Pharmaceuticals Limited (CUV:ASX) has a franking level of 100%.
Clinuvel Pharmaceuticals Limited (CUV:ASX) is classified in the Healthcare.
The current P/E ratio for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 34.60.
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.